

182 Hallucinogens

REFERENCES

1. Abraham HD, Aldridge AM, Gogia P: The psychopharmacology of hallucinogens. *Neuropsychopharmacology* 14: 285, 1996.
2. Dobkin de Rios M, Cardenas M: Plant hallucinogens, shamanism and Nazca ceramics. *J Ethnopharmacol* 2: 233, 1980.
3. Johnston LD, O'Malley PM, Bachman JG, et al: *Monitoring the Future: National Survey Results on Drug Use, 1975–2007, vol. I, Secondary School Students*. NIH Publication No. 08-6418A. Bethesda, MD, National Institute on Drug Abuse, 2008.
4. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: *The NSDUH Report: Use of Specific Hallucinogens: 2006*. Rockville, MD, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2008.
5. Passie T, Halpern JH, Stichtenoth DO, et al: The pharmacology of lysergic acid diethylamide: a review. *CNS Neurosci Ther* 14: 295, 2008.
6. Blaho K, Merigian K, Winberry S, et al: Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication. *Am J Ther* 4: 211, 1997.
7. O'Shea B, Fagan J: Lysergic acid diethylamide. *Ir Med J* 94: 217, 2001.
8. Klock JC, Boerner U, Becker CE: Coma, hyperthermia, and bleeding associated with massive LSD overdose: a report of eight cases. *Clin Toxicol* 8: 191, 1975.
9. Abraham HD, Aldridge AM: Adverse consequences of lysergic acid diethylamide. *Addiction* 88: 1327, 1993.
10. Björnstad K, Hultén P, Beck O, Helander A: Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. *Clin Toxicol (Phila)* 47: 566, 2009.
11. Renfroe CL, Messinger TA: Street drug analysis: an eleven year perspective on illicit drug alteration. *Semin Adolesc Med* 1: 247, 1985.
12. Berger KJ, Guss DA: Mycotoxins revisited: part I. *J Emerg Med* 28: 53, 2005.
13. Berger KJ, Guss DA: Mycotoxins revisited: part II. *J Emerg Med* 28: 175, 2005.
14. McCawley EL, Brummett RE, Dana GW: Convulsions from *Psilocybe* mushroom poisoning. *Proc West Pharmacol Soc* 5: 27, 1962.
15. Bickel M, Ditting T, Watz H, et al: Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after "magic mushroom" abuse. *Eur J Emerg Med* 12: 306, 2005.
16. Davis M: Mescaline: excitatory effects on acoustic startle are blocked by serotonin₂ antagonists. *Psychopharmacology (Berl)* 93: 286, 1987.
17. Halpern JH: Hallucinogens and dissociative agents naturally growing in the United States. *Pharmacol Ther* 102: 131, 2004.
18. Gable RS: Acute toxic effects of club drugs. *J Psychoactive Drugs* 36: 303, 2004.
19. Britt GC, McCance-Katz EF: A brief overview of the clinical pharmacology of "club drugs." *Subst Use Misuse* 40: 1189, 2005.
20. de la Torre R, Farré M, Roset PN, et al: Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. *Ther Drug Monit* 26: 137, 2004.
21. Capela JP, Carmo H, Remião F, et al: Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. *Mol Neurobiol* 39: 210, 2009.
22. Dowling GP, McDonough ET, Bost RO: "Eve" and "ecstasy": a report of five deaths associated with the use of MDEA and MDMA. *JAMA* 257: 1615, 1987.
23. Liechti ME, Kunz I, Kupferschmidt H: Acute medical problems due to Ecstasy use. Case-series of emergency department visits. *Swiss Med Wkly* 135: 652, 2005.
24. Ben-Abraham R, Szold O, Rudick V, Weinbroum AA: "Ecstasy" intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. *Eur J Emerg Med* 10: 309, 2003.
25. Lamberth PG, Ding GK, Nurmi LA: Fatal paramethoxyamphetamine (PMA) poisoning in the Australian Capital Territory. *Med J Aust* 188: 426, 2008.
26. Chang SH, Lai TI, Chen WJ, Fang CC: MDMA-induced acute pulmonary edema in a patient without other organ dysfunction. *Am J Emerg Med* 24: 734, 2006.
27. Budisavljevic MN, Stewart L, Sahn SA, Plotk DW: Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("Ecstasy") abuse. *Am J Med Sci* 326: 89, 2003.
28. Rosenson J, Smollin C, Sporer KA, et al: Patterns of ecstasy-associated hyponatremia in California. *Ann Emerg Med* 49: 164, 2007.
29. Patel MM, Belson MG, Longwater AB, et al: Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. *J Emerg Med* 29: 451, 2005.
30. Patel MM, Wright DW, Ratcliff JJ, Miller MA: Shedding new light on the "safe" club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. *Acad Emerg Med* 11: 208, 2004.
31. Mueller PD, Korey WS: Death by "ecstasy": the serotonin syndrome? *Ann Emerg Med* 32: 377, 1998.
32. Oesterheld JR, Armstrong SC, Cozza KL: Ecstasy: pharmacodynamic and pharmacokinetic interactions. *Psychosomatics* 45: 84, 2004.
33. McCann UD, Eligulashvili V, Ricaurte GA: (+/-)3,4-methylenedioxymethamphetamine ("Ecstasy")-induced serotonin neurotoxicity: clinical studies. *Neuropsychobiology* 42: 11, 2000.
34. Hall AP, Henry JA: Acute toxic effects of "Ecstasy" (MDMA) and related compounds: overview of pathophysiology and clinical management. *Br J Anaesth* 96: 678, 2006.
35. Ramoska E, Sacchetti AD: Propranolol-induced hypertension in treatment of cocaine intoxication. *Ann Emerg Med* 14: 1112, 1985.
36. Fareed FN, Chan G, Hoffman RS: Death temporally related to the use of a beta adrenergic receptor antagonist in cocaine associated myocardial infarction. *J Med Toxicol* 3: 169, 2007.
37. Bordo DJ, Dorfman MA: Ecstasy overdose: rapid cooling leads to successful outcome. *Am J Emerg Med* 22: 326, 2004.
38. Moon J, Cros J: Role of dantrolene in the management of the acute toxic effects of Ecstasy (MDMA). *Br J Anaesth* 99: 146, 2007.
39. Duffy MR, Ferguson C: Role of dantrolene in treatment of heat stroke associated with Ecstasy ingestion. *Br J Anaesth* 98: 148, 2007.
40. Høiseth G, Hjelmeland K, Bachs L: [Phencyclidine—angel dust]. *Tidsskr Nor Laegeforen* 125: 2775, 2005.
41. O'Shea B: Phencyclidine, ketamine, and khat phencyclidine (PCP, DOA, "angel dust," "crystal," "hog"). *Ir Med J* 93: 185, 2000.
42. McCarron MM, Schulz BW, Thompson GA, et al: Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. *Ann Emerg Med* 10: 237, 1981.
43. McCarron MM, Schulz BW, Thompson GA, et al: Acute phencyclidine intoxication: clinical patterns, complications, and treatment. *Ann Emerg Med* 10: 290, 1981.
44. Milhorn HT: Diagnosis and management of phencyclidine intoxication. *Am Fam Physician* 43: 1293, 1991.
45. Eastman JW, Cohen SN: Hypertensive crisis and death associated with phencyclidine poisoning. *JAMA* 231: 1270, 1975.
46. Stein GY, Fradin Z, Ori Y, et al: Phencyclidine-induced multi-organ failure. *Isr Med Assoc J* 7: 535, 2005.
47. Simpson GM, Khajawall AM, Alatorre E, Staples FR: Urinary phencyclidine excretion in chronic abusers. *J Toxicol Clin Toxicol* 19: 1051, 1982.
48. Devane WA, Hanus L, Breuer A, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258: 1946, 1992.
49. Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry* 28: 849, 2004.
50. Dackis CA, Pottash AL, Annitoff W, Gold MS: Persistence of urinary marijuana levels after supervised abstinence. *Am J Psychiatry* 139: 1196, 1982.
51. Halpern JH, Pope HG: Hallucinogens on the Internet: a vast new source of underground drug information. *Am J Psychiatry* 158: 481, 2001.
52. Babu KM, McCurdy CR, Boyer EW: Opioid receptors and legal highs: *Salvia divinorum* and Kratom. *Clin Toxicol (Phila)* 46: 146, 2008.
53. Prisinzano TE: Psychopharmacology of the hallucinogenic sage *Salvia divinorum*. *Life Sci* 78: 527, 2005.
54. Dalgarino P: Subjective effects of *Salvia divinorum*. *J Psychoactive Drugs* 39: 143, 2007.
55. Hitt M, Ettinger DD: Toad toxicity. *N Engl J Med* 314: 1517, 1986.
56. Gowda RM, Cohen RA, Khan IA: Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. *Heart* 89: e14, 2003.
57. Kuo HY, Hsu CW, Chen JH, et al: Life-threatening episode after ingestion of toad eggs: a case report with literature review. *Emerg Med J* 24: 215, 2007.
58. Brubacher JR, Ravikumar PR, Bania T, et al: Treatment of toad venom poisoning with digoxin-specific Fab fragments. *Chest* 110: 1282, 1996.
59. Brubacher JR, Lachman D, Ravikumar PR, Hoffman RS: Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. *Toxicon* 37: 931, 1999.
60. Demetriades AK, Wallman PD, McGuiness A, Gavalas MC: Low cost, high risk: accidental nutmeg intoxication. *Emerg Med J* 22: 223, 2005.
61. Spina SP, Taddei A: Teenagers with Jimson weed (*Datura stramonium*) poisoning. *CJEM* 9: 467, 2007.
62. Wolff K, Winstock AR: Ketamine: from medicine to misuse. *CNS Drugs* 20: 199, 2006.
63. Jansen KL: A review of the nonmedical use of ketamine: use, users and consequences. *J Psychoactive Drugs* 32: 419, 2000.
64. Weiner AL, Vieira L, McKay CA, Bayer MJ: Ketamine abusers presenting to the emergency department: a case series. *J Emerg Med* 18: 447, 2000.
65. Boyer EW: Dextromethorphan abuse. *Pediatr Emerg Care* 20: 858, 2004.
66. Peet M, Peters S: Drug-induced mania. *Drug Saf* 12: 146, 1995.
67. Tanner-Smith EE: Pharmacological content of tablets sold as "ecstasy": results from an online testing service. *Drug Alcohol Depend* 83: 247, 2006. Erratum in: *Drug Alcohol Depend* 93: 190, 2008.
68. Mathias S, Lubman DI, Hides L: Substance-induced psychosis: a diagnostic conundrum. *J Clin Psychiatry* 69: 358, 2008.
69. Caton CL, Drake RE, Hasin DS, et al: Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. *Arch Gen Psychiatry* 62: 137, 2005. Erratum in: *Arch Gen Psychiatry* 62: 493, 2005.
70. Gable RS: Comparison of acute lethal toxicity of commonly abused psychoactive substances. *Addiction* 99: 686, 2004.

USEFUL WEB RESOURCES

American Association of Poison Control Centers—<http://www.aapcc.org/DNN/>
 American Academy of Clinical Toxicology—<http://www.clintox.org/index.cfm>
 European Association of Poisons Centres and Clinical Toxicologists—<http://www.eapctc.org/>
 Asia Pacific Association of Medical Toxicology—<http://www.asiatox.org/>
 South Asian Clinical Toxicology Research Collaboration—<http://www.sactrc.org/>
 TOXBASE: The primary clinical toxicology database of the National Poisons Information Service (free access for UK National Health Service hospital departments and general practices, and National Health Service departments of public health and health protection agency units; available to hospital EDs in Ireland by contract; available to European poison centers whose staff are members of the European Association of Poisons Centres and Clinical Toxicologists; overseas users may be allowed access on payment of a yearly subscription, subject to the approval of the Health Protection Agency)—<http://www.toxbase.org/>
 Erowid ("Erowid is a member-supported organization providing access to reliable, non-judgmental information about psychoactive plants, chemicals, and related issues")—<http://www.erowid.org/general/about/about.shtml>